BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 33901030)

  • 21. Central nervous system ALK-negative anaplastic large cell lymphoma with IRF4/DUSP22 rearrangement.
    Magaki S; Satyadev R; Chen Z; Yung KS; Vinters HV; Kinney MC; Said JW
    Brain Tumor Pathol; 2022 Jan; 39(1):25-34. PubMed ID: 34791573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinicopathological relevance of uniform CD56 expression in anaplastic large cell lymphoma: a retrospective analysis of 18 cases.
    Yu BH; Zhang Y; Xue T; Shui RH; Lu HF; Zhou XY; Zhu XZ; Li XQ
    Diagn Pathol; 2021 Jan; 16(1):1. PubMed ID: 33402163
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ALK expression in extranodal anaplastic large cell lymphoma favours systemic disease with (primary) nodal involvement and a good prognosis and occurs before dissemination.
    ten Berge RL; Oudejans JJ; Ossenkoppele GJ; Pulford K; Willemze R; Falini B; Chott A; Meijer CJ
    J Clin Pathol; 2000 Jun; 53(6):445-50. PubMed ID: 10911802
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Anaplastic large cell lymphomas with the 6p25.3 rearrangement are a heterogeneous group of tumours with a diverse molecular background.
    Díaz de la Pinta FJ; Rodríguez Moreno M; Salgado RN; Carvajal García N; Santonja C; Pérez Buira S; Piris MA; Requena L; Manso R; Rodríguez-Pinilla SM
    Hum Pathol; 2023 Jul; 137():71-78. PubMed ID: 37127078
    [TBL] [Abstract][Full Text] [Related]  

  • 25. TIMP-1 expression in anaplastic large cell lymphoma is usually restricted to macrophages and only seldom observed in tumour cells.
    Rust R; Blokzijl T; Harms G; Lim M; Visser L; Kamps WA; Poppema S; van den Berg A
    J Pathol; 2005 Aug; 206(4):445-50. PubMed ID: 15920698
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of putative pathogenic microRNA and its downstream targets in anaplastic lymphoma kinase-negative anaplastic large cell lymphoma.
    Mehrotra M; Medeiros LJ; Luthra R; Sargent RL; Yao H; Barkoh BA; Singh R; Patel KP
    Hum Pathol; 2014 Oct; 45(10):1995-2005. PubMed ID: 25128227
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Genetic Subtypes of Systemic Anaplastic Large Cell Lymphoma Show Distinct Differences in PD-L1 Expression and Regulatory and Cytotoxic T Cells in the Tumor Microenvironment.
    Ferreira CR; Manohar V; Zhao S; Bangs CD; Cherry A; Azevedo RS; Lage LAPC; Pereira J; Zerbini MCN; Gratzinger D; Natkunam Y
    Appl Immunohistochem Mol Morphol; 2020 Jan; 28(1):10-16. PubMed ID: 31809310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes.
    Laurent C; Delas A; Gaulard P; Haioun C; Moreau A; Xerri L; Traverse-Glehen A; Rousset T; Quintin-Roue I; Petrella T; Emile JF; Amara N; Rochaix P; Chenard-Neu MP; Tasei AM; Menet E; Chomarat H; Costes V; Andrac-Meyer L; Michiels JF; Chassagne-Clement C; de Leval L; Brousset P; Delsol G; Lamant L
    Ann Oncol; 2016 Feb; 27(2):306-14. PubMed ID: 26598546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Expression of the chemokine receptor gene, CCR8, is associated With DUSP22 rearrangements in anaplastic large cell lymphoma.
    Xing X; Flotte TJ; Law ME; Blahnik AJ; Chng WJ; Huang G; Knudson RA; Ketterling RP; Porcher JC; Ansell SM; Sidhu J; Dogan A; Feldman AL
    Appl Immunohistochem Mol Morphol; 2015 Sep; 23(8):580-9. PubMed ID: 25390351
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Extra copies of ALK gene locus is a recurrent genetic aberration and favorable prognostic factor in both ALK-positive and ALK-negative anaplastic large cell lymphomas.
    Yu R; Chen G; Zhou C; Gao Z; Shi Y; Shi Y; Zhou X; Xie J; Liu H; Gong L
    Leuk Res; 2012 Sep; 36(9):1141-6. PubMed ID: 22726922
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Systemic ALK-negative anaplastic large cell lymphoma with distinctive myxoid change and DUSP22 rearrangement.
    Fratoni S; Trawinska MM; Capalbo A; Bernardini L; Fabbretti M; Martini M; Niscola P; Zhao XF
    Virchows Arch; 2022 Dec; 481(6):975-979. PubMed ID: 35879438
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Signal transducer and activator of transcription-3 activation contributes to high tissue inhibitor of metalloproteinase-1 expression in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.
    Lai R; Rassidakis GZ; Medeiros LJ; Ramdas L; Goy AH; Cutler C; Fujio Y; Kunisada K; Amin HM; Gilles F
    Am J Pathol; 2004 Jun; 164(6):2251-8. PubMed ID: 15161657
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and laboratory characteristics of systemic anaplastic large cell lymphoma in Chinese patients.
    Wang YF; Yang YL; Gao ZF; Zhou CJ; Gregg X; Shi YF; Wang J; Yang XF; Ke XY
    J Hematol Oncol; 2012 Jul; 5():38. PubMed ID: 22769020
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anaplastic large cell lymphomas: ALK positive, ALK negative, and primary cutaneous.
    Xing X; Feldman AL
    Adv Anat Pathol; 2015 Jan; 22(1):29-49. PubMed ID: 25461779
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinicopathologic features of 66 cases of anaplastic lymphoma kinase positive and negative systemic anaplastic large cell lymphoma: a comparative study].
    Shi Y; Chen G; Zhou XG; Gong LP; Yu R; Zheng YY; Xie JL; Jin Y
    Zhonghua Bing Li Xue Za Zhi; 2010 Apr; 39(4):235-9. PubMed ID: 20654121
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anaplastic Large Cell Lymphoma: Contemporary Concepts and Optimal Management.
    Shustov A; Soma L
    Cancer Treat Res; 2019; 176():127-144. PubMed ID: 30596216
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Story of survival in anaplastic large cell lymphoma - sometimes more than the anaplastic lymphoma kinase status: An evaluation of pathologic prognostic factors in 102 cases.
    Agrawal K; Shet T; Sridhar E; Dhende S; Sengar M; Arora B; Laskar S; Gujral S; Menon H; Banavali S
    Indian J Pathol Microbiol; 2017; 60(4):533-540. PubMed ID: 29323068
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
    Huang L; Zhang F; Zeng J; Guo H; Liu S; Wei X; Chen F; Jiang X; Liang Z; Liu Y; Li W
    Ann Hematol; 2018 Jan; 97(1):149-159. PubMed ID: 29150811
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recurrent
    Luchtel RA; Zimmermann MT; Hu G; Dasari S; Jiang M; Oishi N; Jacobs HK; Zeng Y; Hundal T; Rech KL; Ketterling RP; Lee JH; Eckloff BW; Yan H; Gaonkar KS; Tian S; Ye Z; Kadin ME; Sidhu J; Jiang L; Voss J; Link BK; Syrbu SI; Facchetti F; Bennani NN; Slager SL; Ordog T; Kocher JP; Cerhan JR; Ansell SM; Feldman AL
    Blood; 2019 Jun; 133(26):2776-2789. PubMed ID: 31101622
    [TBL] [Abstract][Full Text] [Related]  

  • 40. STAT1 is phosphorylated and downregulated by the oncogenic tyrosine kinase NPM-ALK in ALK-positive anaplastic large-cell lymphoma.
    Wu C; Molavi O; Zhang H; Gupta N; Alshareef A; Bone KM; Gopal K; Wu F; Lewis JT; Douglas DN; Kneteman NM; Lai R
    Blood; 2015 Jul; 126(3):336-45. PubMed ID: 25921060
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.